Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 11/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 11/20 | 0.72 |
| ▸ | RECQL | P46063 | 8/20 | 0.72 |
| ▸ | MAPT | P10636 | 7/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.72 |
| ▸ | USP2 | O75604 | 6/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.72 |
| ▸ | TP53 | P04637 | 2/20 | 0.72 |
| ▸ | HBB | P68871 | 1/20 | 0.72 |
| ▸ | THRB | P10828 | 10/20 | 0.65 |
| ▸ | BLM | P54132 | 9/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.65 |
| ▸ | CASP1 | P29466 | 2/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.65 |
| ▸ | S100A4 | P26447 | 6/20 | 0.58 |
| ▸ | PAX8 | Q06710 | 5/20 | 0.58 |
| ▸ | HSP90AA1 | P07900 | 4/20 | 0.58 |
| ▸ | MMP2 | P08253 | 3/20 | 0.57 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.57 |
| ▸ | HTR2B | P41595 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30714406 | 1.00 | MEN1 (0.72) | MEN1KMT2ARECQLMAPTSMN1; SMN2 | |
| SCHEMBL22589699 | 1.00 | MEN1 (0.72) | MEN1KMT2ARECQLMAPTSMN1; SMN2 | |
| SCHEMBL14214095 | 0.89 | MEN1 (0.85) | MEN1KMT2ARECQLMAPTSMN1; SMN2 | |
| SCHEMBL30864532 | 0.88 | PTGS1 (0.65) | MEN1KMT2ARECQLMAPTSMN1; SMN2 | |
| Iremycin SCHEMBL30003721 | 0.87 | MEN1 (0.61) | MEN1KMT2ARECQLMAPTSMN1; SMN2 | |
| Rodorubicin SCHEMBL8693 | 0.87 | MEN1 (0.58) | MEN1KMT2ARECQLMAPTSMN1; SMN2 | |
| Rodorubicin SCHEMBL29352818 | 0.87 | MEN1 (0.58) | MEN1KMT2ARECQLMAPTSMN1; SMN2 | |
| SCHEMBL18593715 | 0.85 | MEN1 (0.62) | MEN1KMT2ARECQLMAPTSMN1; SMN2 | |
| SCHEMBL29711323 | 0.85 | MEN1 (0.63) | MEN1KMT2ARECQLMAPTSMN1; SMN2 | |
| Cosmomycin C SCHEMBL30610383 | 0.85 | PTGS1 (0.62) | MEN1KMT2ARECQLMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12625139-B2 | Methods for modulation of acetyltransferase activity and applications thereof including treatments | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2026-05-12 | — | — | US | claimed |
| US-20250109444-A1 | DNA HYPOMETHYLATION AS A PREDICTIVE MARKER FOR CANCER THERAPY | FRED HUTCHINSON CANCER CENTER (US) | 2025-04-03 | — | — | US | claimed |
| US-20220196660-A1 | Methods for Modulation of Acetyltransferase Activity and Applications Thereof Including Treatments | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2022-06-23 | — | — | US | claimed |
| WO-2020219598-A1 | METHODS FOR MODULATION OF ACETYLTRANSFERASE ACTIVITY AND APPLICATIONS THEREOF INCLUDING TREATMENTS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2020-10-29 | — | — | WO | claimed |
| EP-3149190-A1 | IDENTIFICATION OF NOVEL ANTI-PERSISTER ACTIVITY FOR BORRELIA BURGDORFERI | The Johns Hopkins University (US) | 2017-04-05 | — | — | EP | claimed |
| US-20170058314-A1 | NOVEL METHODOLOGY FOR IDENTIFYING ANTI-PERSISTER ACTIVITY AND ANTIMICROBIAL SUSCEPTIBILITY FOR BORRELIA BURGDORFERI AND OTHER BACTERIA | ZHANG YING (US) | 2017-03-02 | — | — | US | claimed |
| WO-2015171225-A1 | IDENTIFICATION OF NOVEL ANTI-PERSISTER ACTIVITY FOR BORRELIA BURGDORFERI | THE JOHNS HOPKINS UNIVERSITY (US) | 2015-11-12 | — | — | WO | claimed |
| EP-1808169-B1 | Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases | PROTEOTECH INC (US) | 2012-05-30 | — | — | EP | claimed |
| JP-4370072-B2 | — | — | 2009-11-25 | — | — | JP | claimed |
| US-20070191330-A1 | Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases | PROTEOTECH, INC. | 2007-08-16 | — | — | US | claimed |
| EP-1808169-A2 | Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases | Proteotech Inc. (US) | 2007-07-18 | — | — | EP | claimed |
| US-20040152760-A1 | Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases | PROTAMED, INC. | 2004-08-05 | — | — | US | claimed |
| JP-2003532634-A | — | — | 2003-11-05 | — | — | JP | claimed |
| EP-1244435-A2 | POLYHYDROXYLATED AROMATIC COMPOUNDS FOR THE TREATMENT OF AMYLOIDOSIS AND $g(a)-SYNUCLEIN FIBRIL DISEASES | Proteotech Inc. (US) | 2002-10-02 | — | — | EP | claimed |
| US-20010047032-A1 | Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases | PROTAMED, INC. | 2001-11-29 | — | — | US | claimed |
| WO-2001049281-A2 | POLYHYDROXYLATED AROMATIC COMPOUNDS FOR THE TREATMENT OF AMYLOIDOSIS AND α-SYNUCLEIN FIBRIL DISEASES | PROTEOTECH, INC. (US) | 2001-07-12 | — | — | WO | claimed |
| US-4548927-A | Method and agents for raising animal tolerance to oxidant stress-inducing antibiotics | EATON JOHN W (US) | 1985-10-22 | — | — | US | claimed |
| EP-0144402-A1 | METHOD AND AGENTS FOR RAISING ANIMAL TOLERANCE TO OXIDANT STRESS-INDUCING ANTIBIOTICS | EATON, John W. (US) | 1985-06-19 | — | — | EP | claimed |
| WO-1984004679-A1 | METHOD AND AGENTS FOR RAISING ANIMAL TOLERANCE TO OXIDANT STRESS-INDUCING ANTIBIOTICS | EATON JOHN W | 1984-12-06 | — | — | WO | claimed |
| US-12625139-B2 | Methods for modulation of acetyltransferase activity and applications thereof including treatments | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2026-05-12 | — | — | US | disclosed |
| US-20250313900-A1 | COMPOSITIONS AND THERAPEUTIC AGENTS FOR MODULATING INFLAMMATORY RESPONSES ON BOTH TUMOR AND IMMUNE CELLS | THE METHODIST HOSPITAL | 2025-10-09 | — | — | US | disclosed |
| US-20250109444-A1 | DNA HYPOMETHYLATION AS A PREDICTIVE MARKER FOR CANCER THERAPY | FRED HUTCHINSON CANCER CENTER (US) | 2025-04-03 | — | — | US | disclosed |
| US-11421223-B2 | Processes and host cells for genome, pathway, and biomolecular engineering | ENEVOLV, INC. (US) | 2022-08-23 | — | — | US | disclosed |
| US-20220196660-A1 | Methods for Modulation of Acetyltransferase Activity and Applications Thereof Including Treatments | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2022-06-23 | — | — | US | disclosed |
| WO-2020219598-A1 | METHODS FOR MODULATION OF ACETYLTRANSFERASE ACTIVITY AND APPLICATIONS THEREOF INCLUDING TREATMENTS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2020-10-29 | — | — | WO | disclosed |
| US-20190309289-A1 | PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING | ENEVOLV, INC. | 2019-10-10 | — | — | US | disclosed |
| US-10370654-B2 | Processes and host cells for genome, pathway, and biomolecular engineering | ENEVOLV, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| US-20180320170-A1 | PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING | ENEVOLV, INC. | 2018-11-08 | — | — | US | disclosed |
| EP-3321371-A1 | NOVEL METHODS FOR RAPID DRUG SUSCEPTIBILITY TESTING AND DRUG SCREENS FOR GROWING AND NON-GROWING CELLS OF PROKARYOTIC AND EUKARYOTIC ORIGIN | Zhang, Ying (US) | 2018-05-16 | — | — | EP | disclosed |
| US-9944925-B2 | Processes and host cells for genome, pathway, and biomolecular engineering | ENEVOLV, INC. | 2018-04-17 | — | — | US | disclosed |
| CN-107148480-A | Identification of novel antiviral Activity on Borrelia burgdorferi | 张颖 | 2017-09-08 | — | — | CN | disclosed |
| EP-3149190-A1 | IDENTIFICATION OF NOVEL ANTI-PERSISTER ACTIVITY FOR BORRELIA BURGDORFERI | The Johns Hopkins University (US) | 2017-04-05 | — | — | EP | disclosed |
| US-20170058314-A1 | NOVEL METHODOLOGY FOR IDENTIFYING ANTI-PERSISTER ACTIVITY AND ANTIMICROBIAL SUSCEPTIBILITY FOR BORRELIA BURGDORFERI AND OTHER BACTERIA | ZHANG YING (US) | 2017-03-02 | — | — | US | disclosed |
| US-20160186168-A1 | PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING | ENEVOLV, INC. | 2016-06-30 | — | — | US | disclosed |
| EP-3027754-A1 | PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING | enEvolv, Inc. (US) | 2016-06-08 | — | — | EP | disclosed |
| WO-2015171225-A1 | IDENTIFICATION OF NOVEL ANTI-PERSISTER ACTIVITY FOR BORRELIA BURGDORFERI | THE JOHNS HOPKINS UNIVERSITY (US) | 2015-11-12 | — | — | WO | disclosed |
| WO-2015017866-A1 | PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING | ENEVOLV, INC. (US) | 2015-02-05 | — | — | WO | disclosed |
| EP-1808169-B1 | Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases | PROTEOTECH INC (US) | 2012-05-30 | — | — | EP | disclosed |
| US-20110065657-A1 | Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases | PROTAMED, INC. | 2011-03-17 | — | — | US | disclosed |
| US-20070191330-A1 | Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases | PROTEOTECH, INC. | 2007-08-16 | — | — | US | disclosed |
| EP-1808169-A2 | Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases | Proteotech Inc. (US) | 2007-07-18 | — | — | EP | disclosed |
| US-20040152760-A1 | Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases | PROTAMED, INC. | 2004-08-05 | — | — | US | disclosed |
| US-20030082101-A1 | Accelerators for increasing the rate of formation of free radicals and reactive oxygen species | CAVALIER DISCOVERY | 2003-05-01 | — | — | US | disclosed |
| WO-2002100478-A9 | ACCELERATORS FOR INCREASING THE RATE OF FORMATION OF FREE RADICALS AND REACTIVE OXYGEN SPECIES | CAVALIER DISCOVERY (US) | 2003-03-27 | — | — | WO | disclosed |
| WO-2002100478-A2 | ACCELERATORS FOR INCREASING THE RATE OF FORMATION OF FREE RADICALS AND REACTIVE OXYGEN SPECIES | CAVALIER DISCOVERY (US) | 2002-12-19 | — | — | WO | disclosed |
| EP-1244435-A2 | POLYHYDROXYLATED AROMATIC COMPOUNDS FOR THE TREATMENT OF AMYLOIDOSIS AND $g(a)-SYNUCLEIN FIBRIL DISEASES | Proteotech Inc. (US) | 2002-10-02 | — | — | EP | disclosed |
| US-20010047032-A1 | Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases | PROTAMED, INC. | 2001-11-29 | — | — | US | disclosed |
| WO-2001049281-A2 | POLYHYDROXYLATED AROMATIC COMPOUNDS FOR THE TREATMENT OF AMYLOIDOSIS AND α-SYNUCLEIN FIBRIL DISEASES | PROTEOTECH, INC. (US) | 2001-07-12 | — | — | WO | disclosed |
| US-4948880-A | ANTITUMOR AGENTS, REDUCED SIDE EFFECTS | BEHRINGWERKE AKTIENGESELLSCHAFT (DE) | 1990-08-14 | — | — | US | disclosed |
| US-4914191-A | REDUCED SIDE EFFECTS | BEHRINGWERKE AKTIENGESELLSCHAFT (DE) | 1990-04-03 | — | — | US | disclosed |
| US-4795808-A | ANTITUMOR | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-01-03 | — | — | US | disclosed |
| US-4737583-A | ANTITUMOR AGENTS | HOECHST AKTIENGESELLSCHAFT (DE) | 1988-04-12 | — | — | US | disclosed |
| EP-0131942-B1 | ANTHRACYCLINE DERIVATIVES, METHOD FOR THEIR PREPARATION AND THEIR USE AS CYTOSTATIC AGENTS | HOECHST AKTIENGESELLSCHAFT (DE) | 1987-11-11 | — | — | EP | disclosed |
| EP-0207463-A2 | Anthracyclin tetrasaccharides, method for their preparation and their use as cytostatic agents | HOECHST AKTIENGESELLSCHAFT (DE) | 1987-01-07 | — | — | EP | disclosed |
| US-4548927-A | Method and agents for raising animal tolerance to oxidant stress-inducing antibiotics | EATON JOHN W (US) | 1985-10-22 | — | — | US | disclosed |
| EP-0144402-A1 | METHOD AND AGENTS FOR RAISING ANIMAL TOLERANCE TO OXIDANT STRESS-INDUCING ANTIBIOTICS | EATON, John W. (US) | 1985-06-19 | — | — | EP | disclosed |
| EP-0131942-A1 | Anthracycline derivatives, method for their preparation and their use as cytostatic agents | HOECHST AKTIENGESELLSCHAFT (DE) | 1985-01-23 | — | — | EP | disclosed |
| WO-1984004679-A1 | METHOD AND AGENTS FOR RAISING ANIMAL TOLERANCE TO OXIDANT STRESS-INDUCING ANTIBIOTICS | EATON JOHN W | 1984-12-06 | — | — | WO | disclosed |
| WO-1984004679-A1 | METHOD AND AGENTS FOR RAISING ANIMAL TOLERANCE TO OXIDANT STRESS-INDUCING ANTIBIOTICS | EATON JOHN W | 1984-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030082101-A1 | Accelerators for increasing the rate of formation of free radicals and reactive oxygen species | SOD1, SOD3, APEX1 | MEN1 3202/4885KMT2A 3464/4885RECQL 1778/4885 |
| US-20250109444-A1 | DNA HYPOMETHYLATION AS A PREDICTIVE MARKER FOR CANCER THERAPY | DNMT1, DNMT3B, DNMT3A | MEN1 2398/4885KMT2A 67/4885RECQL 2679/4885 |
| US-20250313900-A1 | COMPOSITIONS AND THERAPEUTIC AGENTS FOR MODULATING INFLAMMATORY RESPONSES ON BOTH TUMOR AND IMMUNE CELLS | MIF, CCL2, MPEG1 | MEN1 4240/4885KMT2A 2047/4885RECQL 4103/4885 |
| US-20070191330-A1 | Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases | SNCA, PARK7, HTT | MEN1 4592/4885KMT2A 2079/4885RECQL 1104/4885 |
| US-20010047032-A1 | Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases | SNCA, PARK7, HTT | MEN1 4522/4885KMT2A 1935/4885RECQL 1053/4885 |
| US-20110065657-A1 | Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases | SNCA, PARK7, HTT | MEN1 4592/4885KMT2A 2079/4885RECQL 1104/4885 |
| US-12625139-B2 | Methods for modulation of acetyltransferase activity and applications thereof including treatments | EP300, NAT10, NAT1 | MEN1 2742/4885KMT2A 137/4885RECQL 2815/4885 |
| US-20040152760-A1 | Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases | SNCA, PARK7, HTT | MEN1 4522/4885KMT2A 1935/4885RECQL 1053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.